| --- | --- | |---------------------------------------------|-------| | | | | | | | Investor Presentation April 2019 | | | oncolyticsbiotech.com Nasdaq ONCY TSX | | Forward Looking Statements This presentation contains certain forward looking statements relating to the company's business prospects and the development and commercialization of pelareorep, a first-in-class systemically administered immuno-oncology agent for solid tumors and heme malignancies. These statements are based on management's current ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F | o | REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 | | --- | --- | | | OR | | x | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | For fiscal year ended | | | December 31, 2018 | | | OR | | o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | For the transition period from ____ to ____ OR o SHEL ...

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2018 Results Earnings Conference Call March 8, 2019 8:30 AM ET Company Participants Michael Moore - VP of IR & Corporate Communications Matthew Coffey - President, CEO Kirk Look - CFO Conference Call Participants Wangzhi Li - Ladenburg Thalmann Operator Good morning. My name is Michelle, and I will be your conference operator today. At this time, I would like to welcome everyone to the Oncolytics Biotech Fourth Quarter Results Conference Call. All lines have been pla ...